Intravenous thrombolysis with recombinant tissue plasminogen activator (tPA) is the mainstay therapeutic method of acute ischemic stroke (AIS) with proven clinical benefit (1) and is recommended up to 4.5 h after stroke onset (2). This evidence concerns the gene PLAT and androgen insensitivity syndrome.